AI Deal Activity Remains Strong in Healthcare Amid Decline in Fundraising; Silicon Valley Bank Releases 16th Edition of Healthcare Investments and Exits Report
Silicon Valley Bank (FCNCA), a division of First Citizens Bank, has released its 16th Healthcare Investments and Exits Report, highlighting strong AI deal activity in healthcare despite overall fundraising decline. AI-related healthtech deals doubled in the past 12 months, while non-AI companies saw a 20% decrease over three years.
Key findings show that healthtech accounted for 33% of total healthcare investment, with AI healthtech representing 21%. Back-office AI applications dominated with 44% of all AI investment in H1 2025. In China, biopharma licensing deals reached $3 billion in H1 2025, surpassing 2024 levels. The report also reveals that healthtech raised $8.2 billion in H1 2025, marking the strongest half since H1 2022.
Silicon Valley Bank (FCNCA), una divisione di First Citizens Bank, ha pubblicato il suo 16° Rapporto sugli Investimenti e le Uscite nel Settore Sanitario, evidenziando una forte attività di accordi nel campo dell'IA in ambito sanitario nonostante il calo generale dei finanziamenti. Le operazioni nel settore healthtech legate all'IA sono raddoppiate negli ultimi 12 mesi, mentre le aziende non legate all'IA hanno registrato un calo del 20% in tre anni.
I risultati principali mostrano che l'healthtech ha rappresentato il 33% del totale degli investimenti sanitari, con l'healthtech basato sull'IA che costituisce il 21%. Le applicazioni di IA per la gestione interna hanno dominato con il 44% di tutti gli investimenti in IA nel primo semestre del 2025. In Cina, gli accordi di licenza biopharma hanno raggiunto 3 miliardi di dollari nel primo semestre 2025, superando i livelli del 2024. Il rapporto rivela inoltre che l'healthtech ha raccolto 8,2 miliardi di dollari nel primo semestre 2025, segnando il semestre più forte dal primo semestre 2022.
Silicon Valley Bank (FCNCA), una división de First Citizens Bank, ha publicado su 16.º Informe sobre Inversiones y Salidas en el Sector Salud, destacando una fuerte actividad en acuerdos relacionados con IA en salud a pesar de la disminución general en la recaudación de fondos. Los acuerdos de healthtech relacionados con IA se duplicaron en los últimos 12 meses, mientras que las empresas no relacionadas con IA vieron una disminución del 20% en tres años.
Los hallazgos clave muestran que el healthtech representó el 33% de la inversión total en salud, con el healthtech basado en IA representando el 21%. Las aplicaciones de IA para operaciones internas dominaron con el 44% de toda la inversión en IA en el primer semestre de 2025. En China, los acuerdos de licencias biopharma alcanzaron 3 mil millones de dólares en el primer semestre de 2025, superando los niveles de 2024. El informe también revela que el healthtech recaudó 8,2 mil millones de dólares en el primer semestre de 2025, marcando el semestre más fuerte desde el primer semestre de 2022.
실리콘밸리 은행(FCNCA), 퍼스트 시티즌스 은행의 한 부서가 16번째 헬스케어 투자 및 출구 보고서를 발표했습니다. 전반적인 자금 조달 감소에도 불구하고 헬스케어 분야에서 인공지능(AI) 관련 거래가 활발했음을 강조했습니다. 지난 12개월 동안 AI 관련 헬스테크 거래가 두 배로 증가한 반면, AI 비관련 기업은 3년 동안 20% 감소했습니다.
주요 결과에 따르면 헬스테크가 전체 헬스케어 투자 중 33%를 차지했으며, AI 헬스테크는 21%를 차지했습니다. 백오피스 AI 애플리케이션이 2025년 상반기 AI 투자 중 44%를 점유하며 주도했습니다. 중국에서는 바이오제약 라이선스 거래가 2025년 상반기에 30억 달러에 달해 2024년 수준을 넘어섰습니다. 또한 보고서는 헬스테크가 2025년 상반기에 82억 달러를 모금해 2022년 상반기 이후 가장 강력한 반기였음을 보여줍니다.
Silicon Valley Bank (FCNCA), une division de First Citizens Bank, a publié son 16e rapport sur les investissements et sorties dans le secteur de la santé, mettant en lumière une forte activité des transactions liées à l'IA dans la santé malgré une baisse générale des levées de fonds. Les transactions healthtech liées à l'IA ont doublé au cours des 12 derniers mois, tandis que les entreprises non liées à l'IA ont connu une baisse de 20 % sur trois ans.
Les principales conclusions montrent que le healthtech représentait 33 % de l'investissement total dans la santé, avec le healthtech IA représentant 21 %. Les applications d'IA en back-office ont dominé avec 44 % de tous les investissements en IA au premier semestre 2025. En Chine, les accords de licence biopharmaceutique ont atteint 3 milliards de dollars au premier semestre 2025, dépassant les niveaux de 2024. Le rapport révèle également que le healthtech a levé 8,2 milliards de dollars au premier semestre 2025, marquant le semestre le plus fort depuis le premier semestre 2022.
Silicon Valley Bank (FCNCA), eine Sparte der First Citizens Bank, hat ihren 16. Bericht über Gesundheitsinvestitionen und -austritte veröffentlicht und dabei trotz des allgemeinen Rückgangs bei Fundraising eine starke Aktivität bei KI-Deals im Gesundheitswesen hervorgehoben. KI-bezogene Healthtech-Deals haben sich in den letzten 12 Monaten verdoppelt, während Unternehmen ohne KI in drei Jahren einen Rückgang von 20 % verzeichneten.
Wesentliche Erkenntnisse zeigen, dass Healthtech 33 % der gesamten Gesundheitsinvestitionen ausmachte, wobei KI-Healthtech 21 % repräsentierte. Back-Office-KI-Anwendungen dominierten mit 44 % aller KI-Investitionen im ersten Halbjahr 2025. In China erreichten Biopharma-Lizenzgeschäfte im ersten Halbjahr 2025 3 Milliarden US-Dollar und übertrafen damit das Niveau von 2024. Der Bericht zeigt außerdem, dass Healthtech im ersten Halbjahr 2025 8,2 Milliarden US-Dollar einnahm, was das stärkste Halbjahr seit dem ersten Halbjahr 2022 markiert.
- None.
- Overall healthcare fundraising tracking for lowest amount in over a decade
- Non-AI companies experienced 20% decrease in deal activity over three years
- Diagnostics and tools deal activity has slowed since 2024
- Potential negative impact of tariffs on medical device companies
Insights
SVB reports strong AI-driven healthcare investments despite overall fundraising decline, with healthtech capturing 33% of total healthcare investment.
Silicon Valley Bank's mid-year Healthcare Investments and Exits report reveals a significant contrast in the healthcare investment landscape. While overall fundraising is tracking toward a decade-low, AI-related deals are flourishing across all healthcare sectors. Over the past three years, AI-focused companies have seen robust growth while non-AI companies experienced a
Healthtech emerges as the standout sector, accounting for approximately one-third of total healthcare investment, with AI-based healthtech representing
The report highlights a strategic shift in AI deployment, with
Biopharma investment shows a clear late-stage preference, with Series C+ median pre-money valuations reaching
Medical device investment has maintained consistency between
AI and back-office software driving growth;
"Despite a challenging fundraising environment, we continue to see encouraging signals across the market – particularly in AI investment across all sectors," said Jackie Spencer, Head of Relationship Management for Life Science and Healthcare Banking at Silicon Valley Bank and author of the annual Healthcare Investments and Exits Mid -Year Report. "Healthtech is leading the way, with AI-related deals doubling over the past 12 months. New AI applications are helping to reduce administrative burdens and drive greater efficiency throughout the healthcare system."
Silicon Valley Bank's mid-year 2025 Healthcare Investments and Exits report analyzes and predicts trends for venture capital investing, fundraising, and exits across healthtech, biopharma, diagnostics/tools (dx/tools), and device sectors in the US. The latest edition of the report also includes a spotlight on
Key Findings
AI Spotlight:
- Healthtech stands out: Despite headwinds in the overall market, investors are still spending on healthtech which accounted for about a third of total healthcare investment, with Healthtech AI accounting for
21% . - AI tools attract funding: Mid-way through the year, half of all dollars going to dx/tools companies are going to those that leverage AI.
- Admin tops clinical spend: Back-office applications are taking center stage as AI adoption is focused on reducing administrative burden rather than clinic tasks—accounting for
44% of all AI investment in the first half of 2025.
Investment by Sector:
- Biopharma: Late-stage companies show favor; median biopharma pre-money valuations among Series C+ sat at
$247M $46M $87M - Healthtech: Healthtech remains strong as the sector raised
$8.2 $40M - Dx/Tools: There are silver linings in a slowing market for early-stage diagnostics and tools companies. While deal activity has slowed since 2024, Series A median pre-money valuations and deal sizes hit a five-year high at
$38M $14M - Medical Device: Device investment proves to be consistent, totaling between
$3B $4B
Learn More
For a preview of the 2025 Healthcare Investments and Exits report, please visit: Healthcare Investments and Exits Report | Silicon Valley Bank
To share its deep industry knowledge, Silicon Valley Bank develops various insights reports focused on sectors spanning the innovation economy. For the complete library of Silicon Valley Bank's signature research reports, please visit Market Research Industry Trends & Insights | Silicon Valley Bank (svb.com)
About Silicon Valley Bank
Silicon Valley Bank (SVB), a division of First Citizens Bank, is the bank of some of the world's most innovative companies and investors. SVB provides commercial banking to companies in the technology, life science and healthcare, private equity and venture capital industries. SVB operates in centers of innovation throughout
View original content to download multimedia:https://www.prnewswire.com/news-releases/ai-deal-activity-remains-strong-in-healthcare-amid-decline-in-fundraising-silicon-valley-bank-releases-16th-edition-of-healthcare-investments-and-exits-report-302515867.html
SOURCE Silicon Valley Bank
FAQ
What are the key findings of Silicon Valley Bank's 2025 Healthcare Investments Report for AI investments?
How much did healthtech sector raise in H1 2025 according to Silicon Valley Bank?
What is the state of biopharma investments in China for 2025?
What are the median pre-money valuations for biopharma companies in H1 2025?
How has medical device investment performed since 2022?
